The combination of metformin and liraglutide is more effective than metformin monotherapy in improving hyperandrogenism and reproductive abnormalities.44 A meta-analysis showed that liraglutide has the strongest weight loss effect in PCOS patients compared to metformin, inositol, oseltamide, etc,45 and 510% weight loss can improve the menstrual cycle and ovulation recovery in PCOS patients.46,47 Besides, GLP-1RA can improve cardiovascular disease markers such as adiponectin in the treatment of PCOS patients, thus playing a protective role in cardiovascular disease and benefiting PCOS.30 Currently, clinical trials of GLP-1RA in PCOS are based on weight loss effects.33,34,48,49 Consistent with these results, in this study, PCOS mice showed significant weight loss after semaglutide treatment
doi: 10.1371/journal.pone.0110886 84 DuffieldAJThomsonCD
While tirzepatide's primary therapeutic targets are metabolic disorders, emerging research has begun exploring potential secondary effects on inflammatory pathways and immune function
Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist that mimics the action of the naturally occurring hormone glucagon-like peptide-1